ClinicalTrials.gov
public full text
Public Domain
177LuPSMA in Renal Cell Carcinoma
This study aims to evaluate the efficacy and safety of 177Lu-PSMA-617 as a systemic therapy in patients with PSMA-positive advanced clear cell renal cell carcinoma (ccRCC). The name of the study drug involved in this research study is: -177Lu-PSMA-617 (a type of radioligand therapy)
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- 68Ga-PSMA PET in the Renal Cell Carcinoma#897921
- Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617#1031473
- A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma#911182
- GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma#866972
- Radiopharmaceutical Treatment of Advanced Kidney Cancer#426760
Record · ID 1174088
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive